Last reviewed · How we verify
Lacosamide Injectable Product
Lacosamide Injectable Product is a Small molecule drug developed by University of North Carolina, Chapel Hill. It is currently FDA-approved.
Lacosamide is a small molecule that acts as a sodium channel alpha subunit blocker. It is used to treat conditions such as coma, electrographic status epilepticus, brain injuries, and brain ischemia, often in combination with other medications.
At a glance
| Generic name | Lacosamide Injectable Product |
|---|---|
| Sponsor | University of North Carolina, Chapel Hill |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Antiseizure Medication in Seizure Networks at Early Acute Brain Injury (PHASE4)
- Treatment of ELectroencephalographic STatus Epilepticus After Cardiopulmonary Resuscitation-2 (TELSTAR-2) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lacosamide Injectable Product CI brief — competitive landscape report
- Lacosamide Injectable Product updates RSS · CI watch RSS
- University of North Carolina, Chapel Hill portfolio CI
Frequently asked questions about Lacosamide Injectable Product
What is Lacosamide Injectable Product?
Who makes Lacosamide Injectable Product?
What development phase is Lacosamide Injectable Product in?
Related
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing